Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
Understanding the effect of vaccination on emerging SARS-CoV-2 variants of concern is of increasing importance. Here, James et al. report that two doses of vaccination with the Pfizer-BioNTech vaccine induce more robust immune responses to the B.1.1.7 and B.1.351 SARS-CoV-2 lineages than does natura...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-08-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-021-25167-5 |
| _version_ | 1818422109677813760 |
|---|---|
| author | Donal T. Skelly Adam C. Harding Javier Gilbert-Jaramillo Michael L. Knight Stephanie Longet Anthony Brown Sandra Adele Emily Adland Helen Brown Medawar Laboratory Team Tom Tipton Lizzie Stafford Alexander J. Mentzer Síle A. Johnson Ali Amini OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical Group Tiong Kit Tan Lisa Schimanski Kuan-Ying A. Huang Pramila Rijal PITCH (Protective Immunity T cells in Health Care Worker) Study Group C-MORE/PHOSP-C Group John Frater Philip Goulder Christopher P. Conlon Katie Jeffery Christina Dold Andrew J. Pollard Alex Sigal Tulio de Oliveira Alain R. Townsend Paul Klenerman Susanna J. Dunachie Eleanor Barnes Miles W. Carroll William S. James |
| author_facet | Donal T. Skelly Adam C. Harding Javier Gilbert-Jaramillo Michael L. Knight Stephanie Longet Anthony Brown Sandra Adele Emily Adland Helen Brown Medawar Laboratory Team Tom Tipton Lizzie Stafford Alexander J. Mentzer Síle A. Johnson Ali Amini OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical Group Tiong Kit Tan Lisa Schimanski Kuan-Ying A. Huang Pramila Rijal PITCH (Protective Immunity T cells in Health Care Worker) Study Group C-MORE/PHOSP-C Group John Frater Philip Goulder Christopher P. Conlon Katie Jeffery Christina Dold Andrew J. Pollard Alex Sigal Tulio de Oliveira Alain R. Townsend Paul Klenerman Susanna J. Dunachie Eleanor Barnes Miles W. Carroll William S. James |
| author_sort | Donal T. Skelly |
| collection | DOAJ |
| description | Understanding the effect of vaccination on emerging SARS-CoV-2 variants of concern is of increasing importance. Here, James et al. report that two doses of vaccination with the Pfizer-BioNTech vaccine induce more robust immune responses to the B.1.1.7 and B.1.351 SARS-CoV-2 lineages than does natural infection. |
| first_indexed | 2024-12-14T13:21:02Z |
| format | Article |
| id | doaj.art-2028f3a39a5c4516bfd1ae04c2a4f499 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-14T13:21:02Z |
| publishDate | 2021-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-2028f3a39a5c4516bfd1ae04c2a4f4992022-12-21T22:59:56ZengNature PortfolioNature Communications2041-17232021-08-0112111210.1038/s41467-021-25167-5Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concernDonal T. Skelly0Adam C. Harding1Javier Gilbert-Jaramillo2Michael L. Knight3Stephanie Longet4Anthony Brown5Sandra Adele6Emily Adland7Helen Brown8Medawar Laboratory TeamTom Tipton9Lizzie Stafford10Alexander J. Mentzer11Síle A. Johnson12Ali Amini13OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical GroupTiong Kit Tan14Lisa Schimanski15Kuan-Ying A. Huang16Pramila Rijal17PITCH (Protective Immunity T cells in Health Care Worker) Study GroupC-MORE/PHOSP-C GroupJohn Frater18Philip Goulder19Christopher P. Conlon20Katie Jeffery21Christina Dold22Andrew J. Pollard23Alex Sigal24Tulio de Oliveira25Alain R. Townsend26Paul Klenerman27Susanna J. Dunachie28Eleanor Barnes29Miles W. Carroll30William S. James31Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of OxfordJames and Lillian Martin Centre, Sir William Dunn School of Pathology, University of OxfordJames and Lillian Martin Centre, Sir William Dunn School of Pathology, University of OxfordJames and Lillian Martin Centre, Sir William Dunn School of Pathology, University of OxfordPublic Health EnglandPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of OxfordPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of OxfordPeter Medawar Building for Pathogen Research, Department of Paediatrics, University of OxfordPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of OxfordPublic Health EnglandNuffield Department of Medicine, University of OxfordWellcome Centre for Human Genetics, University of OxfordOxford University Hospitals NHS Foundation TrustPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of OxfordMRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of OxfordMRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of OxfordDepartment of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, and Taipei Medical UniversityMRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of OxfordPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of OxfordPeter Medawar Building for Pathogen Research, Department of Paediatrics, University of OxfordNuffield Department of Medicine, University of OxfordOxford University Hospitals NHS Foundation TrustOxford Vaccine Group, Department of Paediatrics, University of OxfordOxford Vaccine Group, Department of Paediatrics, University of OxfordAfrica Health Research InstituteSchool of Laboratory Medicine and Medical Sciences, University of KwaZulu-NatalMRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of OxfordPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of OxfordPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of OxfordPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of OxfordPublic Health EnglandJames and Lillian Martin Centre, Sir William Dunn School of Pathology, University of OxfordUnderstanding the effect of vaccination on emerging SARS-CoV-2 variants of concern is of increasing importance. Here, James et al. report that two doses of vaccination with the Pfizer-BioNTech vaccine induce more robust immune responses to the B.1.1.7 and B.1.351 SARS-CoV-2 lineages than does natural infection.https://doi.org/10.1038/s41467-021-25167-5 |
| spellingShingle | Donal T. Skelly Adam C. Harding Javier Gilbert-Jaramillo Michael L. Knight Stephanie Longet Anthony Brown Sandra Adele Emily Adland Helen Brown Medawar Laboratory Team Tom Tipton Lizzie Stafford Alexander J. Mentzer Síle A. Johnson Ali Amini OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical Group Tiong Kit Tan Lisa Schimanski Kuan-Ying A. Huang Pramila Rijal PITCH (Protective Immunity T cells in Health Care Worker) Study Group C-MORE/PHOSP-C Group John Frater Philip Goulder Christopher P. Conlon Katie Jeffery Christina Dold Andrew J. Pollard Alex Sigal Tulio de Oliveira Alain R. Townsend Paul Klenerman Susanna J. Dunachie Eleanor Barnes Miles W. Carroll William S. James Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern Nature Communications |
| title | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
| title_full | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
| title_fullStr | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
| title_full_unstemmed | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
| title_short | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
| title_sort | two doses of sars cov 2 vaccination induce robust immune responses to emerging sars cov 2 variants of concern |
| url | https://doi.org/10.1038/s41467-021-25167-5 |
| work_keys_str_mv | AT donaltskelly twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT adamcharding twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT javiergilbertjaramillo twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT michaellknight twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT stephanielonget twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT anthonybrown twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT sandraadele twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT emilyadland twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT helenbrown twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT medawarlaboratoryteam twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT tomtipton twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT lizziestafford twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT alexanderjmentzer twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT sileajohnson twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT aliamini twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT opticoxfordprotectivetcellimmunologyforcovid19clinicalgroup twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT tiongkittan twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT lisaschimanski twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT kuanyingahuang twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT pramilarijal twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT pitchprotectiveimmunitytcellsinhealthcareworkerstudygroup twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT cmorephospcgroup twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT johnfrater twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT philipgoulder twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT christopherpconlon twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT katiejeffery twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT christinadold twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT andrewjpollard twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT alexsigal twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT tuliodeoliveira twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT alainrtownsend twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT paulklenerman twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT susannajdunachie twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT eleanorbarnes twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT mileswcarroll twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT williamsjames twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern |